Immunofoco

Focus: Immunofoco is a Shanghai-based biotechnology company focused on autologous CAR-T cell therapies for hematologic and solid tumors. The company is at Series A stage with an early-stage pipeline spanning multiple oncology indications.

Cell Therapy

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

SERIES A

Open Jobs

About Immunofoco

AI assessmentNot Hiring

No open roles listed right now. Follow Immunofoco to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Mid-stage

1 Phase 3+

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

IMV102 treatment

Relapsed/Refractory Multiple Myeloma

Phase 1

Clinical Trials (1)

NCT07493135A Study of IMV102 in Patients With Relapsed/Refractory Multiple Myeloma

Phase 1

Help build intelligence for Immunofoco

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Exposure to high-value CAR-T cell therapy platform with Phase 3 program in gastric adenocarcinoma, a large unmet need
Early-stage company offers opportunity to shape culture, processes, and strategic direction from the ground up
Diversified pipeline of 5 programs targeting multiple cancer types positions company for multiple value inflection points

Watch Out For

Zero active job openings at time of data collection signals minimal near-term hiring or potential organizational constraints
Series A stage with undisclosed funding means limited visibility into runway, cash position, and path to profitability

Generated by Claude from Immunofoco's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Claudin 18.2 CAR-T

Gastric Cancer

Phase 1

Clinical Trials (1)

NCT05472857Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression

Phase 1

IMV101 treatment

Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Phase 1

Clinical Trials (1)

NCT07376642A Phase I/IIa, Open-label, Single-center, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of IMV101 as a Single Agent in Subjects With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Phase 1

IMC002 injection

Advanced Digestive System Tumor

Phase 1

Clinical Trials (1)

NCT05946226A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

Phase 1

CAR T cells

Gastric Adenocarcinoma

Phase 3

Clinical Trials (1)

NCT07103668A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients

Phase 3

Open Jobs (0)

No open positions listed yet.

Interview Prep Quick Facts

Portfolio: 5 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

5 pipeline

Marketed

Pipeline